Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
07:38pm, Sunday, 23'rd Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesday, Fe
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
10:40am, Friday, 21'st Feb 2025
Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
01:00pm, Wednesday, 12'th Feb 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for
Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum
09:56am, Thursday, 06'th Feb 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed t
Are Medical Stocks Lagging Agenus (AGEN) This Year?
10:41am, Wednesday, 05'th Feb 2025
Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilim
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
02:48pm, Wednesday, 22'nd Jan 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncolo
What Makes Agenus (AGEN) a New Buy Stock
01:01pm, Monday, 20'th Jan 2025
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
10:40am, Monday, 20'th Jan 2025
Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
07:30am, Wednesday, 18'th Dec 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus ba
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
07:30am, Thursday, 05'th Dec 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
08:15am, Wednesday, 27'th Nov 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizin
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Healthcare To Contact Him Directly To Discuss Their Options
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Tuesday, 19'th Nov 2024
Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:37am, Monday, 18'th Nov 2024
The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
